Sugi Predict

Sugi Predict / Compounds / SCHEMBL123047

SCHEMBL123047

SCHEMBL123047

CC(C)N(C(=O)OC(C)(C)C)c1ncc(Br)s1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.60
▸ FFAR2 O15552 1/20 0.35
▸ SSTR4 P31391 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ FPR3 P25089 2/20 0.32
▸ FPR2 P25090 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ PAX8 Q06710 1/20 0.32
▸ PDPK1 O15530 1/20 0.32
▸ FBP1 P09467 2/20 0.30
▸ MAPK10 P53779 1/20 0.30
▸ AAK1 Q2M2I8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1370205 0.89 USP30 (0.49) USP30FFAR2SSTR4ALDH1A1FPR3
SCHEMBL20468298 0.82 USP30 (0.43) USP30FFAR2SSTR4SMN1; SMN2NPC1
SCHEMBL12715430 0.81 PAX8 (0.41) USP30FFAR2SSTR4SMN1; SMN2NPC1
SCHEMBL13593843 0.81 USP30 (0.58) USP30ALDH1A1PDPK1
SCHEMBL27739666 0.80 USP30 (0.39) USP30FFAR2SSTR4SMN1; SMN2NPC1
SCHEMBL1428351 0.79 USP30 (0.37) USP30FFAR2SMN1; SMN2NPC1LMNA
SCHEMBL19260006 0.79 USP30 (0.56) USP30PDPK1AAK1
SCHEMBL23451253 0.79 USP30 (0.39) USP30FFAR2SSTR4SMN1; SMN2NPC1
SCHEMBL16529805 0.78 MLYCD (0.40) USP30SSTR4SMN1; SMN2ALDH1A1FPR3
SCHEMBL16513226 0.76 MLYCD (0.38) USP30SSTR4SMN1; SMN2ALDH1A1FPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3416960-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2021-12-01 — — EP disclosed
WO-2017141036-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LIMITED (GB) 2017-08-24 — — WO disclosed
US-9242977-B2 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. (JP) 2016-01-26 — — US disclosed
US-20150111865-A1 Trk-INHIBITING COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2015-04-23 — — US disclosed
EP-2300466-B1 IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-08-06 — — EP disclosed
EP-2300466-B1 IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-08-06 — — EP disclosed
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 — — EP disclosed
US-8410128-B2 Triazolopyridine compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 — — US disclosed
US-8410128-B2 Triazolopyridine compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 — — US disclosed
US-8410128-B2 Triazolopyridine compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 — — US disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
US-20100029649-A1 PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-02-04 — — US disclosed
US-20100029649-A1 PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-02-04 — — US disclosed
WO-2009155388-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-23 — — WO disclosed
WO-2009155388-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-23 — — WO disclosed
WO-2009155389-A1 TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-23 — — WO disclosed
WO-2009155389-A1 TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 USP30 2275/4885FFAR2 1853/4885SSTR4 2673/4885
US-20150111865-A1 Trk-INHIBITING COMPOUND LTK, ROR1, TEC USP30 3050/4885FFAR2 1678/4885SSTR4 2485/4885
US-20100029649-A1 PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS LIMK1, LIMK2, MAPK1 USP30 3930/4885FFAR2 3688/4885SSTR4 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.